Piramal Pharma has disclosed receipt of an Environment, Social, and Governance (ESG) Rating of ‘68.5’ for the Financial Year 2024-25. The rating was assigned by SES ESG Research Pvt. Ltd. based on publicly available data for that year. Notably, the company confirmed it did not formally engage SES ESG for this assessment, as the report was prepared voluntarily by the research firm.
ESG Rating Disclosure for FY 2024-25
Piramal Pharma Limited has made a regulatory disclosure concerning its recent Environment, Social, and Governance (ESG) assessment. The company noted that it received information on March 20, 2026, regarding an ESG Rating assigned for the Financial Year 2024-25.
Key Rating Details
The external assessment was conducted by SES ESG Research Pvt. Ltd (‘SES ESG’). The resulting ESG Rating provided to Piramal Pharma for the specified fiscal year was ‘68.5’. This rating is based solely on data made available by the Company in the public domain for FY 2024-25.
Voluntary Assessment Confirmation
The Company explicitly stated that it has not engaged SES ESG for the purpose of obtaining an ESG Rating. The report and rating were prepared voluntarily by SES ESG, based on the ESG factors reported publicly by Piramal Pharma.
Public Dissemination
This intimation regarding the ESG rating has been made public, and relevant information, including a link to the published rating on the SES ESG website, has been uploaded to the Company’s official portal for stakeholder records.
Source: BSE
